Hepatology
Review | Assessing the risk of surgery in patients with cirrhosis
10 Apr, 2023 | 13:20h | UTCAssessing the risk of surgery in patients with cirrhosis – Hepatology Communications
Global epidemiology of cirrhosis — Etiology, trends and predictions
6 Apr, 2023 | 13:27h | UTC
Commentary on Twitter
New content online: Global epidemiology of cirrhosis — aetiology, trends and predictions https://t.co/EbgDWTjOyI pic.twitter.com/Cj7KFoWtLi
— Nature Reviews Gastroenterology & Hepatology (@NatRevGastroHep) March 28, 2023
RCT | Comparable efficacy of cefotaxime, ceftriaxone, and ciprofloxacin in treating spontaneous bacterial peritonitis
3 Apr, 2023 | 14:01h | UTCSummary: This multicenter, prospective, open-label, randomized controlled trial compared the efficacy of cefotaxime, ceftriaxone, and ciprofloxacin as initial treatments for spontaneous bacterial peritonitis (SBP) in patients with cirrhosis and ascites. The study included 261 patients aged 16 to 75, with liver cirrhosis, ascites, and a polymorphonuclear cell count of >250/mm3. Researchers performed follow-up paracentesis at 48 hours to evaluate the assigned antibiotics, and assessed resolution rates at 120 and 168 hours of treatment.
The primary endpoint, resolution rates at 120 hours, showed no statistically significant difference between the groups: 67.8% for cefotaxime, 77.0% for ceftriaxone, and 73.6% for ciprofloxacin. One-month mortality rates were also similar. The study concluded that these antibiotics are equally effective as initial treatments for SBP, particularly for community-acquired infections, when administered based on response-guided therapy.
Article: Response-Guided Therapy With Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis: A Randomized Trial: A Validation Study of 2021 AASLD Practice Guidance for SBP – American Journal of Gastroenterology (free for a limited period)
Overcoming size disparity in liver transplant access: prioritizing smaller donors for smaller candidates
3 Apr, 2023 | 13:41h | UTCAssociation of Body Surface Area With Access to Deceased Donor Liver Transplant and Novel Allocation Policies – JAMA Surgery (free for a limited period)
Invited Commentary: Addressing Size-Based Disparities in Liver Transplant – JAMA Surgery (free for a limited period)
Commentary on Twitter
In this study, liver waitlist candidates with the smallest body surface areas had a disadvantage due to size. Prioritizing allocation of smaller liver donors to smaller candidates may help overcome this disparity. https://t.co/p5F76Hgzm0
— JAMA Surgery (@JAMASurgery) March 30, 2023
RCT | Efficacy and safety of colesevelam for the treatment of bile acid diarrhea
30 Mar, 2023 | 14:06h | UTCEfficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo-controlled, phase 4 clinical trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Commentary on Twitter
New research – Borup et al – Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo controlled, phase 4 clinical trialhttps://t.co/m1r0heRgjX#gitwitter #BAD #diarrhoea pic.twitter.com/zk1TnZFS6b
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) February 7, 2023
Review | Recompensation in cirrhosis: current evidence and future directions
29 Mar, 2023 | 13:24h | UTCRecompensation in Cirrhosis: Current Evidence and Future Directions – Journal of Clinical and Experimental Hepatology (free for a limited period)
Cohort Study | Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated
29 Mar, 2023 | 13:02h | UTC
Phase 2 RCT | Semaglutide did not improve fibrosis in NASH-related cirrhosis
27 Mar, 2023 | 13:01h | UTCCommentary: Semaglutide Well-Tolerated, But Shows Lack of Improvement in Liver Fibrosis – HCP Live
Commentary on Twitter
New research – Loomba et al – Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trialhttps://t.co/qkydKMpVfO#NASH #NAFLD #cirrhosis #gitwitter #livertwitter #medtwitter @DrLoomba pic.twitter.com/2A1dylSiq3
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) March 17, 2023
RCT | Time-restricted eating not more effective than daily calorie restriction for managing nonalcoholic fatty liver disease
21 Mar, 2023 | 13:38h | UTCSummary: The TREATY-FLD randomized clinical trial investigated the effects of time-restricted eating (TRE) versus daily calorie restriction (DCR) on intrahepatic triglyceride (IHTG) content and metabolic risk factors in patients with obesity and nonalcoholic fatty liver disease (NAFLD).
Participants were randomly assigned to either TRE (eating only between 8:00 am and 4:00 pm) or DCR (habitual meal timing) and instructed to maintain a diet of 1500 to 1800 kcal/d for men and 1200 to 1500 kcal/d for women for 12 months.
The study found that the IHTG content was reduced by 6.9% in the TRE group and 7.9% in the DCR group after 12 months, a difference that was not statistically significant. Furthermore, TRE did not produce additional benefits for reducing body weight, liver stiffness, or metabolic risk factors compared with DCR.
The study supports that the main focus of a diet for managing NAFLD is caloric restriction, which can be achieved both with a TRE strategy or without a TRE strategy with similar results.
Commentary on Twitter
TREATY-FLD RCT found that time-restricted eating did not produce additional benefits for reducing intrahepatic triglyceride content, body fat and metabolic risk factors vs daily-calorie-restriction among adults with obesity and NAFLD. https://t.co/it2n4o9Th1
— JAMA Network Open (@JAMANetworkOpen) March 17, 2023
CDC recommends HBV screening at least once in a lifetime for all adults aged ≥18 years
13 Mar, 2023 | 15:14h | UTCSummary: The Centers for Disease Control and Prevention (CDC) has issued new recommendations for screening and testing for hepatitis B virus (HBV) infection in the US.
The recommendations include screening for HBV infection at least once in a lifetime for adults aged ≥18 years and more frequent testing for persons at increased risk for HBV infection. The risk groups include:
- Persons incarcerated or formerly incarcerated in jail, prison, or other detention settings.
- Persons with a history of sexually transmitted infections or multiple sex partners.
- Persons with a history of hepatitis C virus infection.
The CDC recommends using the triple panel (HBsAg, anti-HBs, and total anti-HBc) for initial screening to help identify persons who have an active HBV infection, have resolved infection and might be susceptible to reactivation, are susceptible and need vaccination, or are vaccinated.
Commentaries:
Universal Adult Hepatitis B Screening and Vaccination as the Path to Elimination – JAMA
CDC recommends hepatitis B screening for all adults – CIDRAP
CDC Recommends Universal Screening for Hepatitis B Virus – HCP Live
Commentary on Twitter
CDC recommends that all adults get tested for #HepatitisB at least once in their life. Ask your doctor if you’ve been tested. Learn more: https://t.co/kLBZyQYZtQ @CDCMMWR pic.twitter.com/EBkQ9s4MsQ
— CDC (@CDCgov) March 9, 2023
Minimum platelet count threshold before invasive procedures in cirrhosis: evolution of the guidelines
13 Mar, 2023 | 14:36h | UTC
AASLD guidance on the clinical assessment and management of nonalcoholic fatty liver disease
10 Mar, 2023 | 14:36h | UTCRelated:
Management of NAFLD in primary care settings – Liver International
Non-alcoholic fatty liver disease: A patient guideline – JHEP Reports
AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease
22 Feb, 2023 | 12:37h | UTCRelated:
Management of NAFLD in primary care settings – Liver International
Non-alcoholic fatty liver disease: A patient guideline – JHEP Reports
RCT | Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease
20 Feb, 2023 | 12:27h | UTCSummary: The article reports on a randomized trial that compared the effects of alternate-day fasting (ADF) combined with exercise, fasting alone, or exercise alone in adults with obesity and non-alcoholic fatty liver disease (NAFLD). After three months, the combination of ADF and exercise significantly reduced intrahepatic triglyceride content, body weight, fat mass, waist circumference, and alanine transaminase levels compared to the control group. The intervention seems promising for patients with fatty liver disease who want to improve their health without using medications.
Article: Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: A randomized controlled trial – Cell Metabolism (link to abstract – $ for full-text)
News Release: Alternate-day fasting could be a good option for patients with fatty liver disease – University of Illinois Chicago
Current status of liver transplantation for non-B non-C liver cirrhosis and hepatocellular carcinoma
17 Feb, 2023 | 12:36h | UTC
RCT | Orlistat and a low-carb diet show promising results for the treatment of Metabolic-Associated Fatty Liver Disease
16 Feb, 2023 | 15:07h | UTCSummary: The study aimed to compare the effects of orlistat or a high-protein/lower-carbohydrate diet with a control diet in Asian patients with obesity and metabolic-associated fatty liver disease (MAFLD) over 24 weeks. The primary endpoint was the relative change in liver fat content (LFC) assessed by MRI-PDFF. A total of 118 patients were randomly assigned to the control group, orlistat group, or experimental diet group. All three groups demonstrated improvement in liver steatosis at week 24, with the orlistat group and the experimental diet group both showing a significant decrease in LFC compared to the control group.*
*Note: This summary was created through the collaboration of a medical editor and ChatGPT.
Review | Diagnosis and management of autoimmune hepatitis
7 Feb, 2023 | 14:14h | UTCDiagnosis and management of autoimmune hepatitis – The BMJ
Podcast | Hemochromatosis pearls
7 Feb, 2023 | 13:53h | UTC#380 Hemochromatosis with Elliot Tapper – The Curbsiders
Post-transplant biliary complications: advances in pathophysiology, diagnosis, and treatment
3 Feb, 2023 | 14:01h | UTC
Cohort Study | Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol-related cirrhosis
24 Jan, 2023 | 14:14h | UTC
Cross-sectional study | Non-heavy alcohol use associated with liver fibrosis and ‘nonalcoholic’ steatohepatitis
20 Jan, 2023 | 14:29h | UTCNon-heavy alcohol use associates with liver fibrosis and ‘nonalcoholic’ steatohepatitis in the Framingham Heart Study – Clinical Gastroenterology and Hepatology (link to abstract – $ for full-text)
Commentary: Study finds non-heavy alcohol use associated with liver fibrosis – Boston University School of Medicine
AGA clinical practice update on diagnosis and management of acute hepatic porphyrias
17 Jan, 2023 | 13:19h | UTC
Review | Liver intensive care for the general intensivist
17 Jan, 2023 | 12:59h | UTCLiver intensive care for the general intensivist – Anaesthesia
Development and validation of a prognostic nomogram for older patients with acute-on-chronic liver diseases
15 Jan, 2023 | 19:46h | UTCSee also: dynamic nomogram
Review | The pathogenesis and therapeutic strategies of heat stroke-induced liver injury
13 Jan, 2023 | 13:07h | UTCThe pathogenesis and therapeutic strategies of heat stroke-induced liver injury – Critical Care